Clinical Trial Update: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of nivolumab and axitinib in anti-PD-1 refractory advanced melanoma has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Axitinib (Axitinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Yana Najjar | Conditions: Advanced Melanoma, Unresectable Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2025-07-15